⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Antares Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Antares Therapeutics
↗Boston, USA
Antares Therapeutics is a biotechnology company dedicated to developing transformational, first-in-class precision medicines. The company focuses on addressing validated but historically 'undruggable' targets, particularly in oncology and other serious diseases with high unmet medical needs.
Leveraging an integrated drug discovery platform, Antares combines advanced computational chemistry, predictive sciences, and experimental biology. The company was founded in 2025 following a spinout from Scorpion Therapeutics and has established significant research collaborations, including a major agreement with Novartis to discover and develop novel cancer therapies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$10M-$50M
Founded:2025
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$177M
Investors:Omega Funds, Atlas Venture
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical (entering clinic in 2026)
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Novartis (Collaboration for cancer drug discovery), Pierre Fabre Laboratories
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Adam Friedman - CEO
Mark Chao - CMO
Erica Jackson - CSO
Board Members:Jeff Albers, Shelley Chu, Keith Flaherty, Jean-François Formela, Sir Menelas Pangalos
LINKS
Website:antaresrx.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Antares Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.